The Substance Abuse and Mental Health Services Administration (SAMHSA) and National Association of State Alcohol and Drug Abuse Directors, Inc. (NASADAD) Annual Meeting bring together Single State Agency Directors for alcohol and other drug services, state Prevention Coordinators, Treatment Coordinators, Women’s Services Coordinators, and other state and national stakeholders that work on substance use, misuse, and disorders. The meeting is a forum to hear about the latest substance use trends and practices; to engage in interactive discussions on emerging issues; and share information on model programs and strategies used across the prevention, treatment, and recovery system.
Due to health and safety concerns and the uncertainty of COVID-19, we have made the difficult decision to cancel the face-to-face SAMHSA & NASADAD Annual Meeting. Instead, the Annual Meeting will be held virtually this year, July 13, 15, and 17, 2020.
There will be no fee to participate; however, we will require that you register. A link to register for the Annual Meeting will be posted here soon.
Thank you for your patience as we navigate these changing times. More information will be available soon.
As the country confronts the coronavirus (COVID-19), those with substance use disorders are particularly at risk NIDA: COVID-19 potential implications for individuals with SUDs. Single State Agencies (SSAs) for alcohol and drug services are working closely with their service providers, state and federal partners, and local public and private sector partners to address the threat of the coronavirus. This webpage provides federal guidance and state actions taken by SSAs to date. It is not intended to be exhaustive but is meant to highlight key actions and resources that may help other states and territories as they prepare for and respond to the virus outbreak. The website will be updated periodically.
Find all of our available resources here.
In April of 2019, NASADAD sent an inquiry to the Single State Agencies for alcohol and other drug services requesting information on how they were using the State Targeted Response (STR) and State Opioid Response (SOR) grants to address the opioid crisis in their States. The results of the inquiry were summarized into State-specific profiles highlighting prevention, treatment, overdose reversal, and recovery support efforts. Below are brief analyses of the most common ways States have used STR and SOR funds for prevention, treatment, overdose reversal, recovery support, and examples of innovative State initiatives.
Overdose Reversal Initiatives
Recovery Support Initiatives
In 2018, NASADAD developed a timeline of the State Targeted Response to the Opioid Crisis (STR) and State Opioid Response (SOR) grant programs. The timeline outlines key dates, such as: when grants were authorized; when Congress appropriated funds; when funding opportunity announcements (FOAs) were released; funding award periods for States for each of the grant programs; and more. NASADAD has updated the timeline to reflect two recent developments:
- In December 2019, Congress appropriated level funding of $1.5 billion for the State Opioid Response (SOR) grant program, and noted that “stimulant abuse” would be an allowable use of SOR funds in FY 2020.
- In February 2020, the Administration released its proposed budget for FY 2021 and included a request of $1.585 billion for SOR, an increase of $85 million compared to FY 2020.
Access the updated STR/SOR timeline here.
On February 10, 2020, the Administration released “A Budget for America’s Future,” its budget proposal for fiscal year (FY) 2021 (October 1, 2020-September 30, 2021). NASADAD developed an overview of the Administration’s proposed funding levels for the Association’s priority programs within the Department of Health and Human Services (HHS), as well as select programs within the Department of Justice (DOJ) and the Office of National Drug Control Policy (ONDCP). The document compares the President’s FY 2021 proposal to the final FY 2020 funding levels and provides language from the Administration’s Congressional Justifications.
Access the chart here
NASADAD is pleased to announce the release of an Overview of and Recommendations Regarding Electronic Nicotine Delivery Systems (ENDS). The overview:
- Offers background on e-cigarettes and reviews the scope of the problem, especially among youth;
- Outlines federal actions over the past several years, including recent steps to raise the minimum age of legal tobacco product access to 21;
- Describes the Food & Drug Administration’s (FDA) role in regulating the sale of tobacco products;
- Describes the State alcohol & drug agencies’ role in tobacco control, with a particular focus on Synar; and
- Offers NASADAD’s position and recommendations related to ENDS.
On December 19, 2019, Congress passed a final FY 2020 appropriations deal. This document outlines the final funding levels for NASADAD’s priority programs within the Department of Health and Human Services (HHS), the Department of Justice (DOJ), and the White House Office of National Drug Control Policy (ONDCP), including language from the Administration’s Congressional Justifications, as well as the House and Senate Appropriations Committees’ bill reports and final appropriations bill reports.
NASADAD has released an updated appropriations overview to outline the the Senate Appropriations Committee’s Commerce, Justice, Science, and Related Agencies (CJS) bill, a $70.833 billion funding bill that is $6.7 billion above the FY 2019 enacted level. The bill funds the Department of Justice (DOJ) at $32.446 billion and provides $378 million for Comprehensive Addiction and Recovery Act (CARA) programs, including $90 million for the Second Chance Act grants which offer substance use treatment, employment assistance, and other rehabilitation services. This appropriations update also summarizes proposed FY 2020 funding for the Department of Health and Human Services (HHS) and the Office of National Drug Control Policy (ONDCP).